Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology · Los Angeles, CA
NPI
1104144690
Since 2010
Specialty
Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology
Code 2084N0402X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
10833 Le Conte Ave
Los Angeles, CA, 90095
Phone (310) 825-0867
Groups this clinician bills Medicare through
Medicare paid, 2023
$2,400
20 services
Medicare patients, 2023
11
Average age 34
Drug cost, 2024
$317K
290 prescriptions
Company payments, 2025
$53K
From 18 companies
Medicare prescription drug claims, 2024
In 2024, the drug Rajsekar R Rajaraman prescribed most often to Medicare patients was Clobazam, with 59 prescriptions and refills. In total Rajsekar R Rajaraman wrote 290 Medicare prescriptions that cost $317K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-16.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Clobazam Generic | 59 | 63 | Under 11 | $13K |
| Lacosamide Generic | 31 | 31 | Under 11 | $5,580 |
| Xcopri Cenobamate | 26 | 26 | Under 11 | $29K |
| Levetiracetam Generic | 25 | 33 | Under 11 | $632 |
| Lamictal Lamotrigine | 25 | 47 | Under 11 | $39K |
| Topamax Topiramate | 12 | 12 | Under 11 | $38K |
| Fycompa Perampanel | 12 | 12 | Under 11 | $17K |
| Topiramate Generic | 12 | 12 | Under 11 | $108 |
| Rufinamide Generic | 12 | 12 | Under 11 | $10K |
| Zonisamide Generic | 11 | 25 | Under 11 | $320 |
| Hyftor Sirolimus | 11 | 11 | Under 11 | $68K |
Brand drugs: 108 claims; generic drugs: 182 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajsekar R Rajaraman $53K ($53K in general payments such as food, travel and fees) from 18 companies. The largest payer was ACADIA Pharmaceuticals Inc with $25K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.